<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559166</url>
  </required_header>
  <id_info>
    <org_study_id>B-2660-101</org_study_id>
    <nct_id>NCT03559166</nct_id>
  </id_info>
  <brief_title>First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis</brief_title>
  <official_title>A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in Human single ascending dose followed by multiple ascending doses in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, double-blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>2 weeks</time_frame>
    <description>AEs will be assessed by determining the incidence, severity, and dose relationship of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any observed changes in clinical safety laboratory results</measure>
    <time_frame>2 weeks</time_frame>
    <description>Assessed by reviewing any observed changes in CBC, serum chemistry or urinalysis from baseline by dose. Results in subjects dosed with BLD-2660 treatment will be compared to those dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any observed changes in physical examinations</measure>
    <time_frame>2 weeks</time_frame>
    <description>Assessed by reviewing any observed changes in physical examinations from baseline by dose. Results in subjects dosed with BLD-2660 will be compared to those dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any observed changes in vital signs</measure>
    <time_frame>2 weeks</time_frame>
    <description>Assessed by reviewing any observed changes in vital signs from baseline by dose. Results in subjects dosed with BLD-2660 will be compared to those dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any observed changes in ECG</measure>
    <time_frame>2 weeks</time_frame>
    <description>Assessed by reviewing any observed changes in ECG from baseline by dose. Results in subjects dosed with BLD-2660 will be compared to those dosed with placebo.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>cohort 1a - starting dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 1b- first SAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 1c-2nd SAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 1d-3rd SAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 1e-4th SAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2a-1st MAD cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2b-2nd MAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2c-3rd MAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2d-4th MAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2e-5th MAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2F-6th MAD escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-2660</intervention_name>
    <description>Randomized to active product or placebo</description>
    <arm_group_label>cohort 1a - starting dose</arm_group_label>
    <arm_group_label>cohort 1b- first SAD escalation</arm_group_label>
    <arm_group_label>cohort 1c-2nd SAD escalation</arm_group_label>
    <arm_group_label>cohort 1d-3rd SAD escalation</arm_group_label>
    <arm_group_label>cohort 1e-4th SAD escalation</arm_group_label>
    <arm_group_label>cohort 2F-6th MAD escalation</arm_group_label>
    <arm_group_label>cohort 2a-1st MAD cohort</arm_group_label>
    <arm_group_label>cohort 2b-2nd MAD escalation</arm_group_label>
    <arm_group_label>cohort 2c-3rd MAD escalation</arm_group_label>
    <arm_group_label>cohort 2d-4th MAD escalation</arm_group_label>
    <arm_group_label>cohort 2e-5th MAD escalation</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Agree to no smoking or alcohol or illegal substance 48 hours prior to dosing

          -  Have a negative urine drug screen/alcohol breath test on admission to clinic

          -  Agree to use highly effective, double barrier contraception (both male and female
             partners) during the study and for 30 days following completion of dosing

          -  Females of childbearing potential must have a negative serum pregnancy test at
             Screening and a negative urine pregnancy test on Day -1

          -  Normal BMI except liver fibrosis participants (BMI 18 to â‰¤35 kg/m2)

          -  Be in general good health

          -  Clinical laboratory values within normal range

          -  Lung fibrosis participants-a diagnosis of lung fibrosis,

          -  Liver fibrosis participants-a diagnosis of liver fibrosis; some abnormal laboratory
             values will be acceptable for the following; platelet count, albumin, serum creatinine
             and neutrophil-leukocyte ration

        Exclusion Criteria:

          -  Presence of any underlying physical or psychological medical condition that, in the
             opinion of the Investigator, would make it unlikely that the subject will complete the
             study per protocol

          -  History or presence of alcoholism or drug abuse within the 2 years prior to the first
             study drug administration, and unwillingness to be totally abstinent during the dosing
             period

          -  Blood donation or significant blood loss within 60 days prior to the first study drug
             administration

          -  Plasma donation within 7 days prior to the first study drug administration

          -  Administration of investigational product (IP) in another trial within 30 days prior
             to the first study drug administration, or five half-lives, whichever is longer

          -  Females who are pregnant or lactating

          -  Surgery within the past 3 months prior to the first study drug administration
             determined by the PI to be clinically relevant

          -  Failure to satisfy the PI of fitness to participate for any other reason

          -  Active infection or history of recurrent infections

          -  Active malignancy and history of malignancy in the past 5 years, with the exception of
             completely excised basal cell carcinoma or low grade cervical intraepithelial
             neoplasia

          -  Chronic obstructive pulmonary disease

          -  Antibiotic treatment within 3 months

          -  Chronic medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Snyder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

